Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small

Yoshitaka Saito1, Yoh Takekuma1, Masaki Kobayashi2

  • 1Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.

Abstract

Insights

Histamine type 2 receptor antagonists (H2RAs) do not impact the anti-tumor efficacy of gefitinib in non-small cell lung cancer (NSCLC) patients. This study found no significant difference in progression-free survival when H2RAs were co-administered with gefitinib.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Gefitinib is a standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
  • Acid suppressants (AS) may reduce gefitinib's efficacy by decreasing its solubility.
  • The compatibility of different AS with gefitinib requires further investigation.

Purpose of the Study:

  • To evaluate the effect of histamine type 2 receptor antagonists (H2RAs) on the anti-tumor efficacy of gefitinib in NSCLC patients.
  • To determine if H2RAs can be safely co-administered with gefitinib without compromising treatment outcomes.

Main Methods:

  • Retrospective analysis of 87 NSCLC patients treated with gefitinib.
  • Comparison of patients co-administered H2RA with a control group not receiving AS.
  • Primary endpoint: progression-free survival (PFS); Secondary endpoints: overall survival (OS), overall response rate (ORR), and adverse effects.

Main Results:

  • Median PFS was 8.0 months for the H2RA group and 9.0 months for the control group (p=0.82).
  • H2RA co-administration was associated with significantly less liver dysfunction.
  • No significant differences were observed in skin toxicity, diarrhea, PFS, or OS between groups.

Conclusions:

  • Concomitant administration of H2RA with gefitinib does not negatively affect gefitinib's efficacy.
  • H2RAs may reduce the incidence of liver dysfunction in patients receiving gefitinib.
  • H2RAs are not a risk factor for worse PFS or OS when co-administered with gefitinib.

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
772
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
412
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
484
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
311
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K